Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 10:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 126 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Varicella-zoster Virus Infection Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

NCT00578175
View directory record Official record
Conditions
Varicella, Rubella, Mumps, Measles
Interventions
Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®, Prevnar®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 14 Months
Enrollment
1,851 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
141
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 11, 2026, 10:53 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination

NCT04403139
View directory record Official record
Conditions
Varicella Zoster Virus Infection
Interventions
Shingrix
Drug
Lead sponsor
University of Washington
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 11, 2026, 10:53 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age

NCT07742644
View directory record Official record
Conditions
Measles, Mumps, Rubella, Varicella (Chickenpox), Measles-Mumps-Rubella+Chickenpox Vaccine
Interventions
MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
1,860 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
38
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Huntington Park, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 2 Interventional

Dextromethorphan Versus Placebo for Neuropathic Pain

NCT00001344
View directory record Official record
Conditions
Diabetic Neuropathies, Herpes Zoster, Neuralgia
Interventions
dextromethorphan
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 11, 2026, 10:53 PM EDT
Terminated Phase 3 Interventional

A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia

NCT02412917
View directory record Official record
Conditions
Shingles, Herpes Zoster, Postherpetic Neuralgia
Interventions
FV-100, valacyclovir
Drug
Lead sponsor
ContraVir Pharmaceuticals, Inc.
Industry
Eligibility
30 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 1 Interventional

Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox

NCT00001125
View directory record Official record
Conditions
HIV Infections, Chickenpox
Interventions
Varicella Virus Vaccine (Live)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
22
States / cities
Long Beach, California • Los Angeles, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates

NCT01519570
View directory record Official record
Conditions
Herpes Zoster Disease
Interventions
An informational packet regarding shingles and the HZV was sent to patients identified by the EMR
Other
Lead sponsor
Ohio State University
Other
Eligibility
60 Years and older
Enrollment
2,589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 2 Interventional

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

NCT03604406
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
Interventions
Varicella Zoster Vaccine, Placebo Injection
Biological · Other
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
5
States / cities
Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 3 Interventional

Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

NCT00209352
View directory record Official record
Conditions
VZV Infection After Bone Marrow Transplantation
Interventions
Acyclovir
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 11, 2026, 10:53 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

NCT05703607
View directory record Official record
Conditions
Shingles, Herpes Zoster Infection, Human
Interventions
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection, Candidate 3: PF-07921186: VZV modRNA Suspension for Injection, Shingrix, Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
35
States / cities
Gilbert, Arizona • Mesa, Arizona • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

NCT05084508
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
41
States / cities
Bryant, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

NCT00580294
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 11, 2026, 10:53 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

NCT05580458
View directory record Official record
Conditions
Herpes Zoster
Interventions
Shingrix
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

NCT01767467
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine (GSK 1437173A), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Inverness, Florida • Chicago, Illinois • Elkhart, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

NCT01954251
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 2 Interventional

Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients

NCT00000953
View directory record Official record
Conditions
HIV Infections, Chickenpox
Interventions
Sorivudine, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Martinez, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

NCT01165177
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
16,165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 11, 2026, 10:53 PM EDT
Active, not recruiting Phase 1 Interventional

iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma

NCT01953900
View directory record Official record
Conditions
Osteosarcoma, Neuroblastoma
Interventions
GD2 T cells, VZV vaccine, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2034
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects

NCT01165203
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Long Beach, California • San Francisco, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Not applicable Interventional

Comparison of 2 Vials of Components of a Synthetic Geranium Oil

NCT00611949
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Geranium oil
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

NCT00920218
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine 1437173A, Placebo vaccine (saline)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

NCT01751165
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Spring Valley, California • Wichita, Kansas • Uniontown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 11, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

NCT00802464
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Pembroke Pines, Florida • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 11, 2026, 10:53 PM EDT